How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,102 results for

Defensive Medicine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5001. Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

Title: A Double-Blinded, Randomized Trial Comparing Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus ddI Plus Nevirapine in Asymptomatic Patients on AZT Monotherapy Who Develop a Mutation at Codon 215 of HIV Reverse Transcriptase in Serum/Plasma Viral RNA Actual Study Completion Date : October 1998 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from (...) the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 13 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers

1999 Clinical Trials

5002. The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex

: March 16, 2012 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: To determine the safety and usefulness of zidovudine (AZT) for the treatment of patients with early symptomatic HIV infection or early AIDS related complex (ARC). The ability of AZT to suppress HIV, to improve body defenses, and to prevent the occurrence (...) Official Title: The Safety and Efficacy of Zidovudine in the Treatment of Patients With Early AIDS Related Complex Actual Study Completion Date : February 1995 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about

1999 Clinical Trials

5003. Extracorporeal Support for Respiratory Insufficiency (ECMO)

of interstitial edema, the defenses of the lung against agents causing ARI, and the ultrastructural pathology and natural history of the disease were virtually unknown. The Task Force indicated a need for Respiratory Care Centers with highly trained personnel that could reduce mortality from ARI. This clinical trial grew out of the Task Force report. Nine participating centers defined ARI in clinical and physiological terms and agreed to a prospective randomized study for 3 years to compare treatment (...) . Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized Primary Purpose: Treatment Study Start Date : June 1974 Actual Study Completion Date : November 1979 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal

1999 Clinical Trials

5004. Effects of Endotoxin in Normal Human Volunteers

Go to Brief Summary: Bacterial infections can progress to a life-threatening illness called septic shock, characterized by low blood pressure and vital organ damage. The syndrome is thought to be caused by parts of the bacteria and by the body s own immune response to the infection. A major bacterial product that interacts with the immune defenses is called endotoxin. This study will examine the body s response to endotoxin in the lungs or bloodstream. When endotoxin is given in small amounts (...) : Treatment Official Title: The Cardiopulmonary Effects of Endotoxin in Normal Human Volunteers Study Start Date : April 6, 1992 Actual Primary Completion Date : March 21, 2007 Actual Study Completion Date : May 17, 2018 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your

1999 Clinical Trials

5005. Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses

the Suction Blister Technique Study Start Date : April 24, 1990 Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : To identify mediators that contribute to the inflammatory process and granuloma formation by comparing mediators collected from healthy volunteers to patients with abnormal regulation of inflammation and patients with host defense defects. [ Time Frame: Ongoing ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) inflammatory response that results in poor healing of recurrent infections. This study will measure and compare amounts of inflammatory mediators (chemicals involved in the inflammatory response) in healthy normal volunteers and in patients with abnormal immune responses. Healthy normal volunteers and patients with host defense defects or excessive inflammation, as in vasculitis syndromes, may be eligible for this study. Patients must be between 6 and 65 years of age. Participants will have eight small

1999 Clinical Trials

5006. A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

than 40 percent of the patients showed shrinkage of their tumors, and some showed evidence for suppression of HIV growth in the body. However, the combination of IFN-A2b with AZT often caused a marked lowering of the white blood cell (WBC) count, especially a type of WBC called the granulocyte (or neutrophil) which is important in the body's defense against infection. Recombinant human GM-CSF is a human protein which is produced in bacteria. It has been shown to cause an increase in the WBC count (...) a type of WBC called the granulocyte (or neutrophil) which is important in the body's defense against infection. Recombinant human GM-CSF is a human protein which is produced in bacteria. It has been shown to cause an increase in the WBC count. AMENDED: 900910 to allow one patient to be treated beyond one year. Original design: GM-CSF, IFN-A2b, and AZT are given every day for 8 weeks. There are 6 patients per dose level. IFN-A2b and GM-CSF are given in two separate injections under the skin

1999 Clinical Trials

5007. A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

boosting.] One of the earliest observations in the HIV epidemic was the demonstration of HIV infection at mucosal surfaces of cells in the genital tract. These data suggest that priming of immune defenses of viral infected cells may be an important component in the strategy of developing an effective HIV vaccine. Direct immunization of relevant mucosal surfaces with a vectored vaccine may stimulate mucosal immunity. The ALVAC-HIV vCP205 immunogen is constructed from a live recombinant canarypox vector (...) of immune defenses of viral infected cells may be an important component in the strategy of developing an effective HIV vaccine. Direct immunization of relevant mucosal surfaces with a vectored vaccine may stimulate mucosal immunity. The ALVAC-HIV vCP205 immunogen is constructed from a live recombinant canarypox vector that has a good safety profile in volunteers and should allow mucosal induction of immunity. This randomized, double-blind trial evaluates the safety of and immune response to vaccination

1999 Clinical Trials

5008. p53 Vaccine for Ovarian Cancer

apart. The peptide will be mixed with the patient s own blood cells and infused into a vein. This group will also receive IL-2, but not GM-CSF. All study candidates will be tested to see if their cancer has a p53 abnormality and if their immune system mounted a defense against it. These tests may include a tumor biopsy (removal of a small part of the tumor for microscopic examination); lymphapheresis (a procedure to take blood, remove white blood cells called lymphocytes, and return the red cells (...) participants Masking: None (Open Label) Primary Purpose: Treatment Official Title: Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary Study Start Date : July 26, 1999 Actual Primary Completion Date : December 17, 2007 Actual Study Completion Date : January 25, 2013 Resource links provided by the National Library of Medicine related topics: related topics: resources: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures

1999 Clinical Trials

5009. Methods in Education for Breast Cancer Genetics

(NCI) ) Study Details Study Description Go to Brief Summary: In 1997, the Genetics Department of the NCI Medicine Branch helped establish a breast cancer genetics program at the National Naval Medical Center s Breast Care Center. Genetic education, counseling, and germline testing for BRCA1 and BRCA2, two genes which confer increased lifetime risks for breast and ovarian cancer, were offered under a Navy IRB-approved study. Sixty participants received education and counseling on that protocol, 49 (...) manner. Condition or disease Intervention/treatment Phase Breast Cancer Ovarian Cancer Other: Genetic Education and Counseling Phase 3 Detailed Description: In October 1995 the National Naval Medical Center opened the only Department of Defense funded Breast Care Center (BCC). Within less than one year the Center was seeing 100 - 200 new patients per week and making 10 - 20 new diagnoses of breast cancer per month. In 1997 we began conducting germline testing for BRCA1 and BRCA2 under an approved

1999 Clinical Trials

5010. Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

: November 4, 1999 Last Update Posted : March 4, 2008 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma (...) of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Study Start Date : September 1998 Study Completion Date : September 2004 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

1999 Clinical Trials

5011. Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)

of Neurological Disorders and Stroke (NINDS) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: Multiple sclerosis (MS) is a disease of the nervous system. The exact cause of MS is unknown, but it is believed to be an autoimmune condition. Autoimmune conditions are diseases that cause the body's immune system and natural defenses to attack healthy cells. In the case of MS, the immune system begins attacking myelin, the cells (...) to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 25 participants Primary Purpose: Treatment Official Title: Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark Study Start Date : February 1998 Study Completion Date : March 2002 Resource links provided by the National Library of Medicine related topics: related topics: Arms

1999 Clinical Trials

5012. [Prevention of acute respiratory infections in healthy young adults by using oral immunomodulators]. (PubMed)

[Prevention of acute respiratory infections in healthy young adults by using oral immunomodulators]. It is a general experience at army posts that right after the joining up period the number of airway infections suddenly increases. The upper and lower airway infections are especially facilitated by the confinement of military barracks, and the high number of smokers among soldiers. In the winter of 1995/96 at an army post of the Hungarian National Defense Forces authors treated 68 healthy (...) , young recruits, aged between 18-23 preventively with an immunomodulant which contains lyophilized bacterial extracts, and placebo. The aim was to try this medicine on healthy adults to prevent or influence acute respiratory infections. In one third of the nine-month long follow-up period, a blind study was carried out, and two thirds of it were spent with a double blind one. The number of airway infections and off duty days was reduced by more than 40% in the group which was treated

1997 Orvosi hetilap

5013. It is easier to confuse a jury than convince a judge: the crisis in medical malpractice. (PubMed)

It is easier to confuse a jury than convince a judge: the crisis in medical malpractice. A study of cervical spine malpractice cases was conducted. Identifying tort reform models may help to resolve a crisis in medical malpractice.To identify tort reform models that may help to resolve a crisis in medical malpractice.Medical malpractice faces a crisis. Insurance rates are exorbitant, yet many injured patients go uncompensated. Physicians practice defensive medicine for fear of suits (...) %). All of the six plaintiff verdicts (average, $4.42 million) and four of the nine settlements (average, $1.6 million) involving surgery that resulted in new postoperative quadriplegia appeared to be appropriate. However, the author could discern "no fault" in cases five defendants had settled, and the surgeons did not deserve to lose. On the other hand, the author found "fault" in five defense verdicts rendered to three newly quadriplegic patients and two with new postoperative root injuries

2002 Spine

5014. Training room management of medical conditions: infectious diseases. (PubMed)

Training room management of medical conditions: infectious diseases. Management of infectious diseases in athletes encompasses a wide range of pathogens, clinical presentations, and treatment options. Certain athletic activities and training regimens may predispose athletes to increased risk of contracting infectious diseases, some of which may limit athletic participation and pose the threat of significant morbidity. The sports medicine physician plays an important role as a first line (...) of defense in preventing, recognizing, and appropriately treating infectious diseases in athletes.

2005 Clinics in Sports Medicine

5015. Consultants' response to clinical complaints. (PubMed)

Consultants' response to clinical complaints. 7767181 1995 07 03 2018 11 13 0959-8138 310 6988 1995 May 06 BMJ (Clinical research ed.) BMJ Consultants' response to clinical complaints. 1200 Mulcahy L L Selwood M M eng Comment Letter Research Support, Non-U.S. Gov't England BMJ 8900488 0959-8138 AIM IM BMJ. 1995 Jan 7;310(6971):27-9 7827550 Attitude of Health Personnel Consultants psychology Defensive Medicine Humans Malpractice Medical Staff, Hospital psychology 1995 5 6 1995 5 6 0 1 1995 5 6 0

Full Text available with Trip Pro

1995 BMJ : British Medical Journal

5016. Resuscitation and patients' views. (PubMed)

Resuscitation and patients' views. 7819875 1995 02 10 2018 11 13 0959-8138 309 6966 1994 Nov 26 BMJ (Clinical research ed.) BMJ Resuscitation and patients' views. 1442-3 Wall J A JA Palmer R N RN eng Letter Comment England BMJ 8900488 0959-8138 AIM IM BMJ. 1994 Aug 6;309(6951):409 8081159 Cardiopulmonary Resuscitation Defensive Medicine Humans Patient Advocacy legislation & jurisprudence Publishing United Kingdom 1994 11 26 1994 11 26 0 1 1994 11 26 0 0 ppublish 7819875 PMC2541349 BMJ. 1994 Jun

Full Text available with Trip Pro

1994 BMJ : British Medical Journal

5017. New meanings for old quotation. (PubMed)

New meanings for old quotation. 7634215 1995 09 14 2008 11 20 0820-3946 153 4 1995 Aug 15 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ New meanings for old quotation. 398 Vandor T T eng Letter Canada CMAJ 9711805 0820-3946 AIM IM Attitude of Health Personnel Defensive Medicine Humans 1995 8 15 1995 8 15 0 1 1995 8 15 0 0 ppublish 7634215 PMC1487256

Full Text available with Trip Pro

1995 CMAJ: Canadian Medical Association Journal

5018. Medicolegal hell in Texas. (PubMed)

paperwork, take time off work for depositions and consultations, and then worry about how insurers will react the next time premiums are due--even if they are cleared. Texas estimates that defensive medicine practised because of legal fears costs the state at least $702 million annually, spending that is bound to continue as long as one lawsuit is filed annually for every 5.3 doctors in the state.

Full Text available with Trip Pro

1995 CMAJ: Canadian Medical Association Journal

5019. Mutual trust. (PubMed)

Mutual trust. 7795467 1995 08 01 2018 11 13 0959-8138 310 6995 1995 Jun 24 BMJ (Clinical research ed.) BMJ Mutual trust. 1670 Collinge S S eng Letter Comment England BMJ 8900488 0959-8138 AIM IM BMJ. 1995 Mar 25;310(6982):756 7711571 Defensive Medicine Hospitals, Public economics Humans Liability, Legal economics Malpractice economics State Medicine economics United Kingdom 1995 6 24 1995 6 24 0 1 1995 6 24 0 0 ppublish 7795467 PMC2550030 BMJ. 1995 Mar 25;310(6982):756 7711571

Full Text available with Trip Pro

1995 BMJ : British Medical Journal

5020. Threat of litigation. How does it affect family practice? (PubMed)

Threat of litigation. How does it affect family practice? 8199515 1994 07 01 2018 11 13 0008-350X 40 1994 Apr Canadian family physician Medecin de famille canadien Can Fam Physician Threat of litigation. How does it affect family practice? 645-8, 655-8 Rosser W W WW eng fre Editorial Canada Can Fam Physician 0120300 0008-350X IM Adaptation, Psychological Canada Defensive Medicine legislation & jurisprudence Humans Malpractice legislation & jurisprudence Physicians, Family psychology 1994 4 1

Full Text available with Trip Pro

1994 Canadian Family Physician

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>